Finch Therapeutics vs Google

About

Finch Therapeutics is a clinical-stage biotechnology company founded in 2015 that develops microbiome medicines targeting the relationship between the gut microbiome and systemic diseases. The company is focused on two primary therapeutic areas: gastrointestinal infections including C. difficile and conditions involving the gut-brain axis including autism spectrum disorder where gut microbiome alterations have been associated with symptom severity. Finch's lead microbiome program CP101 targets recurrent C. difficile infection, competing in the same emerging microbiome therapeutics space as Seres Therapeutics. The company also conducts research on the COMET platform for autism spectrum disorder, exploring whether microbiome restoration can improve behavioral symptoms through the gut-brain connection. Finch has raised over $165M and has conducted multiple clinical trials of its microbiome medicines. The company's autism program represents a particularly innovative and scientifically ambitious program given the emerging evidence that gut microbiome composition influences neurological development and behavior. Finch's work contributes to the broader scientific validation of microbiome medicine as a legitimate therapeutic class beyond C. difficile.